This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
by Zacks Equity Research
Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Alkermes Sinks as FDA Refuses to Approve Depression Drug
by Zacks Equity Research
Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).
Merck (MRK) Beats on Q4 Earnings & Sales as Keytruda Shines
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as sales in fourth-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio (INO) focuses on developing its most advanced candidate, VGX-3100 vaccine, which has been advancing well. Reliance on partners for funds to develop its pipeline candidates is a concern.
Merck (MRK) Q4 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive fourth-quarter sales. However, genericization of key drugs and increasing competition are concerns.
Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe
by Zacks Equity Research
Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer patients in second-line setting in Europe. Shares up.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
by Zacks Equity Research
Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Immunomedics Gets CRL From FDA for Breast Cancer Candidate
by Zacks Equity Research
Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.
NVS or AZN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. AZN: Which Stock Is the Better Value Option?
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
What's in Store for Merck in 2019 After a Solid Run in '18?
by Zacks Equity Research
Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
Moderna (MRNA) Announces Pipeline Progress, Shares Rise
by Zacks Equity Research
Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff
by Zacks Equity Research
Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate
by Zacks Equity Research
Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.
Why the Earnings Surprise Streak Could Continue for Astrazeneca (AZN)
by Zacks Equity Research
Astrazeneca (AZN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Immunomedics Enters Into Supply Deal for Breast Cancer Drug
by Zacks Equity Research
Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.
Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019
by Kinjel Shah
J&J's (JNJ) stock has declined more than 14% since Reuters reported that it knew for decades that its baby powders contained asbestos. It is better to avoid the stock and invest in these three big drug stocks instead.
The Zacks Analyst Blog Highlights: Procter & Gamble, Oracle, United Parcel Service, FedEx and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Oracle, United Parcel Service, FedEx and AstraZeneca
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations
by Zacks Equity Research
Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.
Top Research Reports for Procter & Gamble, Oracle & United Parcel Service
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Oracle (ORCL) and United Parcel Service (UPS).
AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
by Zacks Equity Research
Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.